keyword
MENU ▼
Read by QxMD icon Read
search

secondary CNS lymphoma

keyword
https://www.readbyqxmd.com/read/29327175/microrna-30c-as-a-novel-diagnostic-biomarker-for-primary-and-secondary-b-cell-lymphoma-of-the-cns
#1
Alexander Baraniskin, Monika Chomiak, Guido Ahle, Thomas Gress, Malte Buchholz, Michael Turewicz, Martin Eisenacher, Michelle Margold, Uwe Schlegel, Wolff Schmiegel, Stephan Hahn, Roland Schroers
Primary lymphomas of the central nervous system (PCNSL) are highly aggressive tumors affecting exclusively the CNS, meninges, and eyes. PCNSL must be separated from secondary spread of systemic lymphoma to the CNS (SCNSL), which may occur at diagnosis or relapse of systemic lymphomas. At present, there are no valid methods to distinguish PCNSL from SCNSL based on tumor biopsy because of similar histological presentation. However, SCNSL and PCNSL are different in terms of prognosis and adequate therapy protocols...
January 11, 2018: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29222307/secondary-cns-relapse-in-diffuse-large-b-cell-lymphoma-defining-high-risk-patients-and-optimization-of-prophylaxis-strategies
#2
REVIEW
Kerry J Savage
Despite improvement in survival in diffuse large B-cell lymphoma (DLBCL) with the introduction of rituximab, central nervous system (CNS) relapse continues to represent a clinical challenge. A number of studies have evaluated clinical risk factors in an attempt to identify high-risk patients to direct CNS staging investigations and consider prophylaxis strategies. The CNS International Prognostic Index is a robust and reproducible risk model that can identity patients at high risk of CNS relapse, but its specificity remains limited...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/29222305/biology-of-cns-lymphoma-and-the-potential-of-novel-agents
#3
REVIEW
James L Rubenstein
Primary and secondary CNS lymphomas are aggressive brain tumors that pose an immense challenge to define in terms of molecular pathogenesis, as well as to effectively treat. During the past 10 years improvements in survival have been achieved with the implementation of anti-CD20 immunotherapy and optimization of dose-intensive consolidation strategies. The applications of whole-exome sequencing, comparative genomic hybridization, transcriptional profiling, and examination of the tumor microenvironment, particularly in the context of clinical investigation, provide insights that create a roadmap for the development and implementation of novel targeted agents for this disease...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/29184763/usefulness-of-enhancement-perfusion-mismatch-in-differentiation-of-cns-lymphomas-from-other-enhancing-malignant-tumors-of-the-brain
#4
Pradeep Goyal, Yogesh Kumar, Nishant Gupta, Ajay Malhotra, Saurabh Gupta, Sonali Gupta, Manisha Mangla, Rajiv Mangla
Background: Surgical planning and treatment options for primary or secondary central nervous system lymphomas (PCNSL or SCNSL) are different from other enhancing malignant lesions such as glioblastoma multiforme (GBM), anaplastic gliomas and metastases; so, it is critical to distinguish them preoperatively. We hypothesized that enhancement-perfusion (E-P) mismatch on dynamic susceptibility weighted magnetic resonance (DSC-MR) perfusion imaging which corresponds to low mean relative cerebral blood volume (mean rCBV) in an enhancing portion of the tumor should allow differentiation of CNS lymphomas from other enhancing malignant lesions...
October 2017: Quantitative Imaging in Medicine and Surgery
https://www.readbyqxmd.com/read/29181160/secondary-central-nervous-system-lymphoma-surrounding-a-region-injured-by-subarachnoid-hemorrhage-and-subsequent-aneurysmal-clipping
#5
Yoriko Murata, Yasuhiro Hata, Yoshihiro Noda, Satoshi Matsusaka, Naoki Fukui, Tomohito Kadota, Jun Iwata, Takuya Machida, Takuji Yamagami
The present case study describes a rare case of secondary central nervous system (CNS) lymphoma that infiltrated the dura and leptomeninges around the area injured by subarachnoid hemorrhage and subsequent aneurysmal clipping. Invasion of the CNS was observed by computed tomography as slurred fissures of the right parietal lobe adjacent to the surgery area. Subdural and subarachnoid enhancement overlapping the area injured by past surgical procedures was observed by contrast-enhanced magnetic resonance imaging...
November 2017: Biomedical Reports
https://www.readbyqxmd.com/read/29074098/lorlatinib-in-non-small-cell-lung-cancer-with-alk-or-ros1-rearrangement-an-international-multicentre-open-label-single-arm-first-in-man-phase-1-trial
#6
MULTICENTER STUDY
Alice T Shaw, Enriqueta Felip, Todd M Bauer, Benjamin Besse, Alejandro Navarro, Sophie Postel-Vinay, Justin F Gainor, Melissa Johnson, Jorg Dietrich, Leonard P James, Jill S Clancy, Joseph Chen, Jean-François Martini, Antonello Abbattista, Benjamin J Solomon
BACKGROUND: Most patients with anaplastic lymphoma kinase (ALK)-rearranged or ROS proto-oncogene 1 (ROS1)-rearranged non-small-cell lung cancer (NSCLC) are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops, commonly within the CNS. This study aimed to analyse the safety, efficacy, and pharmacokinetic properties of lorlatinib, a novel, highly potent, selective, and brain-penetrant ALK and ROS1 TKI with preclinical activity against most known resistance mutations, in patients with advanced ALK-positive or ROS1-positive NSCLC...
December 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29038675/secondary-central-nerve-system-lymphoma-with-intratumoral-hemorrhage-suggested-as-intravascular-lymphoma-by-autopsy-a-case-report
#7
Yutaro Suzuki, Hiroaki Tanaka, Kennichiro Suyama, Hidetoshi Mochida, Yoshio Suzuki
Intravascular large B-cell lymphoma (IVL) is a rare type of extranodal diffuse large B-cell lymphoma (DLBCL), which often infiltrates the central nervous system (CNS) during the clinical course. Cerebral hemorrhage in patients with CNS lymphoma at presentation is rare. Herein, we describe a case of secondary CNS lymphoma with intratumoral hemorrhage, which was suggested as IVL from autopsy findings. A 76-year-old Japanese man with a history of treatment for B-cell non-Hodgkin's lymphoma was transferred to our hospital in an ambulance for generalized convulsions...
November 2017: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/28961853/secondary-cns-lymphoma-the-poisoned-needle-in-the-haystack
#8
A J M Ferreri
No abstract text is available yet for this article.
October 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28916896/involvement-of-il-17-in-secondary-brain-injury-after-a-traumatic-brain-injury-in-rats
#9
Tan Li, Yong-Mei Zhang, Dong Han, Rong Hua, Bing-Nan Guo, Shu-Qun Hu, Xian-Liang Yan, Tie Xu
The pro-inflammatory activity of interleukin 17, which is produced by the IL-23/IL-17 axis, has been associated with the pathogenesis of traumatic brain injury (TBI). The study investigated the potential role of IL-17 in secondary brain injury of TBI in a rat model. Our data showed that the levels of IL-17 increased from 6 h to 7 days and peaked at 3 days, in both the CNS and serum, which were consistent with the severity of secondary brain injury. The IL-23 inhibitor suberoylanilide hydroxamic acid (SAHA) treatment markedly decreased the expressions of IL-17 and apoptosis-associated proteins cleaved caspase-3 and increased the protein ratio of Bcl-2 (B cell lymphoma/leukemia-2)/Bax (Bcl-2-associated X protein)...
December 2017: Neuromolecular Medicine
https://www.readbyqxmd.com/read/28861359/intraocular-lymphoma
#10
REVIEW
Li-Juan Tang, Chang-Lin Gu, Ping Zhang
Intraocular lymphoma (IOL) is a rare lymphocytic malignancy which contains two main distinct forms. Primary intraocular lymphoma (PIOL) is mainly a sub-type of primary central nervous system lymphoma (PCNSL). Alternatively, IOL can originate from outside the central nervous system (CNS) by metastasizing to the eye. These tumors are known as secondary intraocular lymphoma (SIOL). The IOL can arise in the retina, uvea, vitreous, Bruch's membrane and optic nerve. There are predominantly of B-cell origin; however there are also rare T-cell variants...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28854563/integrin-alpha-10-cd44-pten-cadherin-11-and-lactoferrin-expressions-are-potential-biomarkers-for-selecting-patients-in-need-of-central-nervous-system-prophylaxis-in-diffuse-large-b-cell-lymphoma
#11
Siria A Lemma, Milla Kuusisto, Kirsi-Maria Haapasaari, Raija Sormunen, Tuula Lehtinen, Tuula Klaavuniemi, Mine Eray, Esa Jantunen, Ylermi Soini, Kaija Vasala, Jan Böhm, Niina Salokorpi, Petri Koivunen, Peeter Karihtala, Jussi Vuoristo, Taina Turpeenniemi-Hujanen, Outi Kuittinen
Central nervous system (CNS) relapse is a devastating complication that occurs in about 5% of diffuse large B-cell lymphoma (DLBCL) patients. Currently, there are no predictive biological markers. We wanted to study potential biomarkers of CNS tropism that play a role in adhesion, migration and/or in the regulation of inflammatory responses. The expression levels of ITGA10, CD44, PTEN, cadherin-11, CDH12, N-cadherin, P-cadherin, lactoferrin and E-cadherin were studied with IHC and IEM. GEP was performed to see whether found expressional changes are regulated at DNA/RNA level...
August 1, 2017: Carcinogenesis
https://www.readbyqxmd.com/read/28768349/-bilateral-hippocampal-primary-cns-lymphoma-unusual-differential-diagnosis-of-rapid-progressive-dementia
#12
Stefan Weidauer, Sylvia Hartmann, Jan Fabricius
We report on a 63-year old man suffering from rapid progressive dementia due to bilateral hippocampal primary CNS lymphoma. Early diagnosis especially in secondary dementia is essential because of potentially treatable aetiologies with regression of cognitive and behaviour abnormalities. Characteristic imaging findings especially in inflammatory and neoplastic lesions affecting the hippocampal structures are discussed.
July 2017: Fortschritte der Neurologie-Psychiatrie
https://www.readbyqxmd.com/read/28611025/how-i-treat-patients-with-aggressive-lymphoma-at-high-risk-of-cns-relapse
#13
REVIEW
Collin K Chin, Chan Yoon Cheah
Central nervous system (CNS) relapses are an uncommon yet devastating complication of non-Hodgkin lymphomas. The identification of patients at high risk of secondary CNS relapse is therefore paramount. Retrospective data indicate prophylactic CNS-directed therapies may reduce the risk of CNS involvement; however, no consensus exists about dose, timing, or route of therapy. In addition, prophylaxis is not without risk of treatment-related complications and morbidity. Here, we present a series of case vignettes highlighting our approach to common dilemmas encountered in routine clinical practice...
August 17, 2017: Blood
https://www.readbyqxmd.com/read/28586279/alectinib-versus-crizotinib-in-untreated-alk-positive-non-small-cell-lung-cancer
#14
RANDOMIZED CONTROLLED TRIAL
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell, Ali Zeaiter, Emmanuel Mitry, Sophie Golding, Bogdana Balas, Johannes Noe, Peter N Morcos, Tony Mok
BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with asymptomatic CNS disease. METHODS: In a randomized, open-label, phase 3 trial, we randomly assigned 303 patients with previously untreated, advanced ALK-positive NSCLC to receive either alectinib (600 mg twice daily) or crizotinib (250 mg twice daily)...
August 31, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28370436/secondary-cns-involvement-of-alk-negative-anaplastic-large-cell-lymphoma
#15
Ajay Major, Zenggang Pan, Manali Kamdar
No abstract text is available yet for this article.
March 28, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28278731/treatment-of-initial-parenchymal-central-nervous-system-involvement-in-systemic-aggressive-b-cell-lymphoma
#16
Marcel Nijland, Anne Jansen, Jeanette K Doorduijn, Roelien H Enting, Jacoline E C Bromberg, Hanneke C Kluin-Nelemans
Central nervous system (CNS) involvement in systemic B-cell non-Hodgkin lymphoma (B-NHL) at diagnosis (sysCNS) is rare. We investigated the outcome of 21 patients with sysCNS, most commonly diffuse large B-cell lymphoma, treated with high dose methotrexate (HD-MTX) and R-CHOP. The median number of cycles of HD-MTX and R-CHOP was 4 (range 1-8) and 6 (range 0-8), respectively. Consolidative whole brain radiotherapy (WBRT) was given to 33% (7/21) patients. With a median follow-up of 44 months the 3-year progression free survival (PFS) and overall survival (OS) were 45% (95%CI 34-56%) and 49% (95%CI 38-60%), respectively...
September 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28237865/the-number-of-extranodal-sites-assessed-by-pet-ct-scan-is-a-powerful-predictor-of-cns-relapse-for-patients-with-diffuse-large-b-cell-lymphoma-an-international-multicenter-study-of-1532-patients-treated-with-chemoimmunotherapy
#17
MULTICENTER STUDY
Tarec Christoffer El-Galaly, Diego Villa, Thomas Yssing Michaelsen, Martin Hutchings, Nabegh George Mikhaeel, Kerry J Savage, Laurie H Sehn, Sally Barrington, Jakob W Hansen, Daniel Smith, Kirsty Rady, Karen J Mylam, Thomas S Larsen, Staffan Holmberg, Maja B Juul, Sabrina Cordua, Michael R Clausen, Kristina B Jensen, Hans E Johnsen, John F Seymour, Joseph M Connors, Peter de Nully Brown, Martin Bøgsted, Chan Y Cheah
PURPOSE: Development of secondary central nervous system involvement (SCNS) in patients with diffuse large B-cell lymphoma is associated with poor outcomes. The CNS International Prognostic Index (CNS-IPI) has been proposed for identifying patients at greatest risk, but the optimal model is unknown. METHODS: We retrospectively analysed patients with diffuse large B-cell lymphoma diagnosed between 2001 and 2013, staged with PET/CT and treated with R-CHOP(-like) regimens...
April 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28178710/diagnosis-and-management-of-leukemic-and-lymphomatous-meningitis
#18
REVIEW
Hemant Murthy, Claudio Anasetti, Ernesto Ayala
BACKGROUND: Leukemic and lymphomatous meningitis is a major presentation of primary or secondary central nervous system (CNS) involvement by aggressive lymphomas or acute leukemia. METHODS: The medical literature and ongoing clinical trials were reviewed on the clinical presentation, diagnosis, prognosis, prevention, and treatment of leukemic and lymphomatous meningitis. RESULTS: Treatment for secondary leukemic and lymphomatous meningitis remains unsatisfactory, and efforts should be made to prevent and treat subclinical disease...
January 2017: Cancer Control: Journal of the Moffitt Cancer Center
https://www.readbyqxmd.com/read/28062425/first-reported-case-of-disseminated-nocardia-kroppenstedtii-sp-nov-infection-presenting-with-brain-abscess-and-endocarditis-in-an-immunocompromised-patient-with-mantle-cell-lymphoma-challenges-in-diagnosis-and-treatment
#19
Aneela Majeed, Hafez Mohammad Ammar Abdullah, Waqas Ullah, Mayar Al Mohajer
A 72-year-old man with a history of blastoid variant stage IV relapsed refractory mantle cell lymphoma presented with new central nervous system (CNS) symptoms. Brain imaging was positive for rim-enhancing lesions along with a mitral valve mass on the echocardiogram. It was a challenge to establish the exact aetiology of these lesions in this patient. He was empirically treated with chemotherapy on the presumption that the brain lesions were secondary to progressive malignancy. However, brain biopsy was negative for malignancy and blood cultures were found positive for Nocardia kroppenstedtii sp nov...
January 6, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/27804873/recent-development-in-the-discovery-of-anaplastic-lymphoma-kinase-alk-inhibitors-for-non-small-cell-lung-cancer
#20
REVIEW
Jingru Liu, Shutao Ma
Non-Small Cell Lung Cancer (NSCLC) is an especially aggressive cancer, the optimal drugs for which are still being developed. The anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase belonging to the insulin receptor superfamily. EML4-ALK fusion gene initially identified in patients with NSCLC in 2007 is defined as a new molecular subset, which is highly sensitive to ALK inhibition. Since the first ALK inhibitor, crizotinib, was approved by the US Food and Drug Administration (FDA) for the treatment of NSCLC patients in 2011, ALK has been identified as a promising target for NSCLC therapy...
2017: Current Medicinal Chemistry
keyword
keyword
101599
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"